

**August 19, 2025**

**BSE Limited**  
P J Towers,  
Dalal Street,  
Mumbai – 400 001

**National Stock Exchange of India Limited**  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051

**Scrip Code: 543904**

**Symbol: MANKIND**

Dear Sir/Madam,

**Subject: Intimation under Regulation 30 & 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015-Incorporation of a Wholly Owned Subsidiary Company in Russia**

---

In continuation of our earlier communication dated April 14, 2025 and pursuant to Regulation 30 & 51 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we wish to inform you that, as disclosed, proposed wholly owned subsidiary has been incorporated in Russia on August 18, 2025 (intimation of the same was received today i.e. August 19, 2025) under the name and style of “Mankind Pharma LLC”.

The detailed disclosures as required under Regulations 30 & 51 of the Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024 (collectively referred as “SEBI Circulars”) were already provided by the Company in its communication dated April 14, 2025.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

**Hitesh Kumar Jain**  
**Company Secretary and Compliance Officer**